Why Sarepta Therapeutics (SRPT) Stock Is Plunging Today

NEW YORK (TheStreet) -- Sarepta Therapeutics  (SRPT) plunged Thursday after the company reported data from its Phase II study of eteplirsen, an experimental drug designed to treat Duchenne muscular dystrophy.

The data from 144 weeks of the study showed a greater decline in walking ability in patients treated with the drug compared to previous updates on the study. Sarepta still plans to file for FDA approval of eteplirsen by the end of the year.

Duchenne muscular dystrophy is a degenerative disease that causes patients to progressively lose muscle function and eventually leads to death.

Must Read: Latest Sarepta Study Update Shows Greater Decline in Walking Ability

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

For much more on the Sarepta data, read TheStreet's Adam Feuerstein's in-depth article here.

The stock was down 19.27% to $20.90 at 10:47 a.m. More than 9 million shares had changed hands, compared to the average volume of 1,354,170.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error